We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00911105
First Posted: June 1, 2009
Last Update Posted: May 5, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
iOMEDICO AG
May 28, 2009
June 1, 2009
May 5, 2016
May 2009
April 2012   (Final data collection date for primary outcome measure)
Time to progression (TTP) [ Time Frame: maximum 3 years per Patient ]
Time to progression (TTP)
Complete list of historical versions of study NCT00911105 on ClinicalTrials.gov Archive Site
  • Overall Response Rate [ Time Frame: maximum 3 years per Patient ]
  • Time to Treatment Discontinuation (TTD) [ Time Frame: maximum 3 years per Patient ]
  • Overall Survival (OS) [ Time Frame: maximum 3 years per Patient ]
  • Safety Profile [ Time Frame: maximum 3 years per Patient ]
  • Dosage of Lenalidomide and Dexamethasone [ Time Frame: maximum 3 years per Patient ]
  • Kidney Function [ Time Frame: maximum 3 years per Patient ]
  • Neutropenia / Infection (Concomitant Medication) [ Time Frame: maximum 3 years per Patient ]
  • Thrombosis Prophylaxis [ Time Frame: maximum 3 years per Patient ]
  • Overall Response Rate
  • Time to Treatment Discontinuation (TTD)
  • Overall Survival (OS)
  • Safety Profile
  • Dosage of Lenalidomide and Dexamethasone
  • Kidney Function [ Time Frame: 3 years per patient ]
  • Neutropenia / Infection (Concomitant Medication)
  • Thrombosis Prophylaxis
Not Provided
Not Provided
 
Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone
Combined Application of Lenalidomide and Desamethasone in the Palliative Therapy of Patients With Multiple Myeloma
Purpose of this non-interventional study is the documentation of efficacy and safety data of multiple myeloma therapy with a combined treatment of Lenalidomide and Dexamethasone in daily routine practice.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients with mutiple myeloma receiving a combination therapy with Lenalidomide and Dexamethasone.
Multiple Myeloma
Not Provided
Patients with multiple myeloma
Patients with multiple myeloma receiving second line therapy or higher.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
101
November 2015
April 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with multiple myeloma with at least one previous therapy.
  • 18 years or older
  • Signed, written informed consent

Exclusion Criteria:

  • Pregnancy or nursing
  • All other exclusion criteria listed in SmPC (summary of product characteristics)
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT00911105
IOM-0810
No
Not Provided
Not Provided
iOMEDICO AG
iOMEDICO AG
Not Provided
Not Provided
iOMEDICO AG
May 2016